WASHINGTON — Immune checkpoint inhibitor (ICI) therapy does not increase mortality in people with preexisting autoimmune diseases, new research has found. Results from a large database analysis of ...

General practitioner examining a patient's hand for signs of rheumatoid arthritis. A breakthrough in cancer and autoimmune disease therapy could unlock a whole new frontier in medicine. Scientists are ...

Clinical and genetic risk factors can help identify individuals at risk for immune checkpoint inhibitor-induced diabetes, according to results of a cohort study. Researchers at an academic integrated ...

A team of researchers at the UCLA Health Jonsson Comprehensive Cancer Center has identified a potential new strategy to prevent, and even reverse, immune checkpoint inhibitor–induced type 1 diabetes, ...

Checkpoint inhibitors transformed cancer treatment, bringing to patients immunotherapies now widely used to treat a range of tumors. But there are different types of checkpoints that interact with the ...

Chimeric antigen receptor (CAR) T-cell therapies pose no special safety issues for cancer patients with comorbid autoimmune diseases, and while so-called checkpoint inhibitors for cancer do come with ...

A nationwide cohort study in Taiwan found a higher risk of psoriasis in cancer patients treated with immune checkpoint inhibitors compared to other therapies. The study analyzed data from 3,188 ...

Cancer represents a key challenge in medical science, manifesting as a disease where the immune system fails to recognize and eliminate tumor cells. The phenomenon of immune evasion by cancer cells ...

A recent case report explains how epitope spread may cause immune checkpoint inhibitor (ICI)–associated bullous pemphigoid (BP). A separate research letter spotlights cases of partial lipodystrophy ...

A team of researchers at the UCLA Health Jonsson Comprehensive Cancer Center has identified a potential new strategy to prevent, and even reverse, immune checkpoint inhibitor–induced type 1 diabetes, ...